Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: phase 2 study (Lynch Syndrome patients)

Blogger's Note: this abstract does not indicate if Lynch Syndrome mutations were included, nor, does it differentiate the response in the scope of urothelial tumors (bladder, renal pelvis, ureter), the Lancet is most often paid-subscription-based

Abstract

Background

No standard treatment exists for patients with platinum-refractory urothelial cancer. Taxanes and vinflunine are commonly used, but response is less than 20% with no survival benefit. In this phase 2 study, we assessed efficacy and tolerability of nanoparticle albumin-bound (nab) paclitaxel in platinum-refractory urothelial cancer.....